# COMPATIBILITY OF PHARMACEUTICAL PRODUCTS AND CONTACT MATERIALS

**Safety Considerations Associated** with Extractables and Leachables

**DENNIS JENKE** 



A JOHN WILEY & SONS, INC., PUBLICATION

### COMPATIBILITY OF PHARMACEUTICAL PRODUCTS AND CONTACT MATERIALS

# COMPATIBILITY OF PHARMACEUTICAL PRODUCTS AND CONTACT MATERIALS

**Safety Considerations Associated** with Extractables and Leachables

**DENNIS JENKE** 



A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2009 by John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey. Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permission.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

#### Library of Congress Cataloging-in-Publication Data:

Jenke, Dennis.

Compatibility of pharmaceutical products and contact materials : safety considerations associated with extractables and leachables / Dennis Jenke.

p.; cm. Includes bibliographical references and index. ISBN 978-0-470-28176-5 (cloth)

1. Drugs-Containers-Safety measures. 2. Drug delivery devices-Safety measures. 3. Leachate. 4. Extracts. I. Title.

[DNLM: 1. Drug Delivery Systems-standards. 2. Consumer Product Safety.

- 3. Drug Contamination-prevention & control. 4. Drug Packaging-standards.
- 5. Drug Stability. QV 785 J52C 2009]

RS159.5.J458 2009 615'.190289—dc22

2008045583

Printed in the United States of America.

## To My Family, In case you were wondering, this is where all that time went.

## **CONTENTS**

PRI	EFACE AND ACKNOWLEDGMENTS	XV		
PAI	PART A GENERAL CONCEPTS			
1.	Introduction	3		
	General Discussion, 3			
	Key Definitions, 6			
	The Interacting Parties, 6			
	Extractables versus Leachables, 7			
	Regulatory Perspectives for Performing Compatibility and/or			
	Safety Assessments, 13			
	The U.S. Food and Drug Administration Guidance for			
	Industry: Container Closure Systems for Packaging Huma	n		
	Drugs and Biologics, 14			
	European Medicines Agency (EMEA) Guideline on Plastic			
	Immediate Packaging Materials, 15			
	FDA Guidance for Industry, Inhalation Products, 18			
	Medical Devices, 20			
	An Overview of Strategies for Performing Safety			
	Assessments, 21			
	The Generalized Strategy for Safety Assessments, 22			
	Moving Forward, 24			
	References, 25			

2.	Nomenclature and General Concepts	27
	General, 27	
	Nomenclature, 27	
	Primary Definitions, 28	
	Constituents of a Material or Construct, 29	
	Classification of Extracting Media, 31	
	Classification of Extraction Strategies, 32	
	Example Extraction Conditions Applied to a Model	
	System, 39	
	Correlation, 43	
	Factors That Influence the Linking of Extractables and	
	Leachables, 44	
	A Hierarchy for Linkages between Extractables and	
	Leachables, 44	
	Decisions Concerning the Required Rigor for Linkages, 47	
	Circumstances Requiring the Linking of Extractables and Leachables, 48	
	Identification and Quantitation, 50	
	Risks and Risk Management, 55	
	Risk Categories Related to Biological Assessment of Medic	าลไ
	Devices, 58	zai
	Risk Categories Related to Assessment of Primary Packagi	ng
	and/or Container–Closure Systems, 58	0
	The General Dimensions of Risk, 64	
	Utilization of Risk Classification Profiles, 68	
	Risk Classification in Indirect Contact Situations, 71	
	The Construct Itself as a Contributor to Risk, 73	
	References, 74	
3.	Extractables, Leachables, and the Product Life Cycle	77
	General, 77	
	Discussion of the Components of the Master Flow Diagram,	78
	Observations, 83	
	Application of the Process Map, 87	
	- -	

### PART B MATERIAL CHARACTERIZATION

91

89

## 4. Material Screening and Characterization

Overview, 91

General Principles, 94

Compendial Compliance, 97

United States Pharmacopeia, 98

Japanese Pharmaceopeia, 101

European Pharmacopeia, 102

Compositional Characterization, General Concepts, 103

Compositional Characterization by Collecting Available Material Information, 104

General, 104

Collecting Extractables Information from the Material Supplier, 106

Compositional Characterization by Material Testing, Extractables Survey, 112

Extractables Survey, 112

Extractables Survey: Extraction, 112

Case Studies: The Influence of Extraction Medium on the Extractables Survey, 121

Extractables Survey: Extract Analysis, 124

Case Study: Extractables Survey for Plastic Tubing Materials, 131

Case Study: Extractables Survey for an Elastomer Used in OINDP, 136

Case Study: Extractables Survey for a Rubber Closure Used with Semisolid Drug Products, 137

Case Study: Extractables Survey for Filter Cartridges Used in Downstream Processing of Pharmaceuticals, 138

Bibliography of Analytical Methods, 139

Reconciliation as a Survey Tool, 140

Case Study: TOC Reconciliation; Characterization of a Polyolefin Material, 141

Use of Extractables Information in Safety Assessment:

Extractables Profile, Total Pool, and Total Available Pool, 142

Extractions to Establish the Total Pool and Total Available Pool, 143

Case Study: Total Pool Determination by Successive Extraction, 145

Recap: Components of a Complete Extractables Assessment, 146

Caveats in Using Extractables Information for Safety Assessment, 149

Chemical Characterization: Device Perspective per ISO 10993-18, 152

References, 154

#### PART C CONSTRUCT QUALIFICATION

157

#### 5. The Prototype Stage

159

General Comments, 159

The Simulation Study, 161

Generating the Simulating Extract, 162

Simulating the Contact Parameters, 164

Simulating the Therapeutic Product, 166

Simulating the Exposure Parameters, 169

Analyzing the Simulating Extract, 171

Case Study: Modeling of the Impact of Solubilizing Agents on Leachables Accumulation, 172

Case Study: Accumulation of Organic Leachables from Plastic Biopharmaceutical Process Containers, 174

Case Study: Accumulation of Label-Related Leachables in a Solid Dosage Form, 179

Case Study: Accumulation of Caprolactam Oligomers Leached from Nylon-6 Material, 180

Application of the Analytical Threshold, 181

The Preliminary Toxicological Assessment, 184

Case Study: Assessment of Cyclohexanone Limits for Containers, 188

Exiting the Prototype Stage, 188 References, 189

#### **6.** The Early Development Stage

191

General Comments, 191

Target Leachables, 192

Method Development, Evaluation, and Validation, 194

Method Development (Optimization), 195

Prerequisites to Method Optimization, 195

Overview of the Method Optimization Process, 197

Conduct of a Method Optimization Study, 200

Primary Performance Assessment, 201

Troubleshooting Guide, 202

Secondary Performance Assessment, 204

System Suitability, 205

Robustness, 205

Exiting Method Development-Optimization, 206

The Method Evaluation Process, 206

General, 206

Aspects of the Evaluation and Validation Processes, 207

	Overview of the Method Evaluation Process, 207 Template for the Conduct of a Method Evaluation Study, Validation, 214 Case Study: Validation of an LC/MS Method for the Quantitation of Leachables from a Packaging System, 2 General, 215 Experimental, 216 Validation Study, 218 Case Study: Validation of an HPLC Method For Quantitatin Stopper Leachables in a Complex Surfactant Vehicle, 2 General, 225 Validation, 225 Exiting the Early Development Stage, 228 References, 228	215 ng
PAI	RT D CONSTRUCT VALIDATION	229
7.	Late Stage Product Development	231
	General: The Migration Study, 231  Design of the Migration Study, 233  EMEA Guideline on Plastic Immediate Packaging  Materials, 233  FDA Guidance, 233  Optimal Design of a Migration Study, 234  Interpretation of the Migration Study: Toxicological  Assessment, 238  Disaster Management, 238  Class A Disaster: Unusual or Unexpected Change in the  Concentration of a Target Leachable, 239  Class B Disaster: A Previously Unobserved Response Is  Obtained During Testing, 241  Documenting a Disaster Investigation, 242  Specificity Check in Drug Product Analysis Methods, 242  Product Stability Issues Associated with Leachables, 244  References, 245	
8.	Submission	249

General Discussion, 249

Dossier Format: The Common Technical Document, 250

	Section 3.2.P.7, Description, 252 Section 3.2.P.2.4, Suitability, 254 Closing Observations, 262 References, 263	
9.	Launch	265
PAl	RT E PRODUCT MAINTENANCE	271
10.	Product Maintenance	273
	General Discussion, 273 Ongoing Quality Control, 275 General, 275 Incoming Raw Materials, 275 Manufactured In-Process Goods, 278 Finished Goods (Final Product), 279 Process of Developing–Implementing QC Extractables Specifications, 281 Change Control, 282 General, 282 Change Control Impact Assessment, 285 Evaluation Recommendation, 295 Factors to Consider When Contemplating Changes to Registered Products, 296 Case Study: Differential Approach, 297	
	Overview, 297 General Test Strategy, 297 Experimental, 298 Results and Discussion, 299 Principles for Judging Toxicological Equivalency, 304 Disaster Management During Product Maintenance, 305 Atypical Manufacturing During Product Maintenance, 30 Product Use Field Issues Encountered During Product Maintenance, 309 Changes in Product Registration Requirements During Product Maintenance, 312 Exiting the Product Maintenance Stage, 313 References, 313	

Contents of the CTD Sections Relevant to Container Closure

Systems and Their Safety Assessment, 252

	CONTENTS	xiii
11.	Retirement	315
12.	Focus on Emerging Concepts	319
	Overview, 319 Plastic Materials used in Manufacturing Applications, 320 General, 320 Regulatory Requirements, 321 Industry Recommendations, 322 Case Study: Leachables Evaluation for Bulk Drug Substance, 326 Process for Performing Extractables and Leachables Assessments for Disposable Materials Used in Bioprocessing, 327 A Matter of Semantics, 328 Best Demonstrated Practices in Extractables Assessments, The Broader Context of Suitability for Use, 337 An Important Practical Consideration, 340 Future Considerations, 342	331
	References, 344	
App	pendix: Materials Used in Pharmaceutical Constructs and	

347

**371** 

**Their Associated Extractables** 

References, 370

**INDEX**